

Protocol Registration Receipt

03/13/2014

Grantor: CDER IND/IDE Number: 106616 Serial Number:

An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD)
Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B

This study has been completed.

Sponsor:	GlaxoSmithKline
Collaborators:	
Information provided by (Responsible Party):	GlaxoSmithKline
ClinicalTrials.gov Identifier:	NCT01323660

► Purpose

This is a phase III multicenter, randomized, double-blind, placebo-controlled, combination and component, two-period, incomplete block design cross-over study using GSK573719/GW642444. The primary objective is to evaluate lung function and exercise endurance time after 12 weeks of once-daily administration of GSK573719/GW642444 Inhalation Powder (125/25mcg and 62.5/25mcg), GSK573719 Inhalation Powder (125mcg and 62.5mcg), GW642444 Inhalation Powder 25 mcg and placebo delivered by a Novel dry powder inhaler (Novel DPI).

Condition	Intervention	Phase
Pulmonary Disease, Chronic Obstructive	Drug: GSK573719/GW642444 125/25 Drug: GSK573719/GW642444 62.5/25 Drug: GSK573719 125 Drug: GSK573719 62.5 Drug: GW642444 25 Device: placebo	Phase 3

Study Type: Interventional

Study Design: Treatment, Crossover Assignment, Double Blind (Subject, Investigator), Randomized, Efficacy Study

Official Title: An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study B

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measure:

- Change From Baseline in Exercise Endurance Time Post-dose at Week 12 of Each Treatment Period [Time Frame: Week 12 of each treatment period (up to Study Week 30)] [Designated as safety issue: No]

Exercise endurance time (EET) post-dose at Week 12 is defined as the EET obtained 3 hours after dosing at Week 12. EET was measured using the externally paced field walking test called the endurance shuttle walk test (ESWT). Analysis performed using a repeated measures model with covariates of period walking speed, mean walking speed, period, treatment, visit, smoking status, center group, visit by period walking speed, visit by mean walking speed and visit by treatment interactions. The model used all available 3-hour post-dose change from baseline EET values recorded on Day 2, Week 6 and Week 12. Baseline was the EET assessment obtained prior to dosing on Day 1 of each period. The mean walking speed for each participant is the mean of the levels used for the ESWT in each of the two treatment periods. The period walking speed for each participant and treatment period is the difference between the level for that participant and period and the mean walking speed for that participant.

- Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at Week 12 of Each Treatment Period [Time Frame: Week 12 of each treatment period (up to Study Week 30)] [Designated as safety issue: No]

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 measurements were taken electronically by spirometry on Day 2, Week 6 and Week 12. Baseline is the FEV1 value recorded pre-dose on Day 1 of each treatment period, mean Baseline is the mean of the Baselines for each participant, and period Baseline is the difference between the Baseline and the mean Baseline in each treatment period for each participant. Clinic visit trough (pre-bronchodilator and pre-dose) FEV1 at Week 12 (Treatment Day 85) is defined as the FEV1 value obtained 24 hours after dosing on Treatment Day 84. Analysis performed using a repeated measures model with covariates of period Baseline, mean Baseline, period, treatment, visit, smoking status, center group, visit by period Baseline, visit by mean Baseline and visit by treatment interactions.

Secondary Outcome Measures:

- Change From Baseline in Inspiratory Capacity (Trough and 3-hours Post-dose) at Week 12 of Each Treatment Period [Time Frame: Week 12 of each treatment period (up to Study Week 30)] [Designated as safety issue: No]

Inspiratory capacity (IC) is defined as the maximum amount of air that can be inhaled into the lungs from the normal resting position after breathing out normally. Baseline is the IC value recorded pre-dose on Day 1 of each treatment period, mean Baseline is the mean of the Baselines for each participant, and period Baseline is the difference between the Baseline and the mean Baseline in each treatment period for each participant. Trough IC is measured pre-dose on Treatment Week 12 of each treatment period. IC 3-hours post-dose is measured from the value obtained 3 hours after dosing on Treatment Week 12 of each treatment period. Analysis performed using a repeated measures model with covariates of period Baseline, mean Baseline, period, treatment, visit, smoking status, center group, visit by period Baseline, visit by mean Baseline and visit by treatment interactions. IC measurements were taken electronically by plethysmography on Day 2, Week 6 and Week 12.

- Change From Baseline in Functional Residual Capacity (Trough and 3-hours Post-dose) at Week 12 of Each Treatment Period [Time Frame: Week 12 of each treatment period (up to Study Week 30)] [Designated as safety issue: No]

Functional Residual Capacity (FRC) is defined as the amount of air still left in the lungs after breathing out normally. Baseline is the FRC value recorded pre-dose on Day 1 of each treatment period, mean Baseline is the mean of the Baselines for each participant, and period Baseline is the difference between the Baseline and the mean Baseline in each treatment period for each participant. Trough FRC is measured pre-dose on Treatment Week 12. FRC 3-hours post-dose is measured from the value obtained 3 hours after dosing on Treatment Week 12. Analysis performed using a repeated measures model with covariates of period Baseline, mean Baseline, period, treatment, visit, smoking status, center group, visit by period Baseline, visit by mean Baseline and visit by treatment interactions. FRC measurements were taken electronically by plethysmography on Day 2, Week 6 and Week 12.

- Change From Baseline in Residual Volume (Trough and 3-hours Post-dose) at Week 12 of Each Treatment Period [Time Frame: Week 12 of each treatment period (up to Study Week 30)] [Designated as safety issue: No]

Residual Volume (RV) is defined as the air that remains in the lungs after breathing out as fully as possible. Baseline is the RV value recorded pre-dose on Day 1 of each treatment period, mean Baseline is the mean of the Baselines for each participant, and period Baseline is the difference between the Baseline and the mean Baseline in each treatment period for each participant. Trough RV is measured pre-dose on Treatment Week 12. RV 3-hours post-dose is measured from the value obtained 3 hours after dosing on Treatment Week 12. Analysis performed using a repeated measures model with covariates of period Baseline, mean Baseline, period, treatment, visit, smoking status, center group, visit by period Baseline, visit by mean Baseline and visit by treatment interactions. RV measurements were taken electronically by plethysmography on Day 2, Week 6 and Week 12.

- Change From Baseline in 3-hours Post-dose FEV1 at Week 12 of Each Treatment Period [Time Frame: Week 12 of each treatment period (up to Study Week 30)] [Designated as safety issue: No]

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Baseline is the FEV1 value recorded pre-dose on Day 1 of each treatment period, mean Baseline is the mean of the Baselines for each participant, and period Baseline is the difference between the Baseline and the mean Baseline in each treatment period for each participant. Clinic visit post-dose FEV1 at Week 12 (Treatment Day 85) is defined as the FEV1 value obtained 3 hours after dosing on Treatment Day 85. Analysis performed using a repeated measures model with covariates of period Baseline, mean Baseline, period, treatment, visit, smoking status, center group, visit by period Baseline, visit by mean Baseline and visit by treatment interactions. 3 hour post-dose FEV1 measurements were taken electronically by spirometry on Day 2, Week 6 and Week 12.

Enrollment: 307

Study Start Date: March 2011

Study Completion Date: July 2012

Primary Completion Date: July 2012

Arms	Assigned Interventions
Experimental: GSK573719/GW642444 125/25 125mcg/25mcg nDPI	Drug: GSK573719 125 125mcg QID Drug: GW642444 25 25mcg QID Device: placebo Comparator QID
Experimental: GSK573719/GW642444 62.5/25 62.5mcg/25mcg nDPI	Drug: GSK573719 62.5 62.5mcg QID Drug: GW642444 25 25mcg QID Device: placebo Comparator QID
Experimental: GSK573719/ 125 125mcg nDPI	Drug: GSK573719/GW642444 125/25 125mcg/ 25mcg QID (Once daily , inhaled) Device: placebo Comparator QID
Experimental: GSK573719 62.5 62.5mcg nDPI	Drug: GSK573719/GW642444 62.5/25 62.5mcg/25mcg QID Device: placebo Comparator QID

Arms	Assigned Interventions
Experimental: GW642444 25 25mcg nDPI	Drug: GSK573719/GW642444 125/25 125mcg/ 25mcg QID (Once daily , inhaled) Drug: GSK573719/GW642444 62.5/25 62.5mcg/25mcg QID Device: placebo Comparator QID
Placebo Comparator: Placebo Plb nDPI	Drug: GSK573719/GW642444 125/25 125mcg/ 25mcg QID (Once daily , inhaled) Drug: GSK573719/GW642444 62.5/25 62.5mcg/25mcg QID Drug: GSK573719 125 125mcg QID Drug: GSK573719 62.5 62.5mcg QID Drug: GW642444 25 25mcg QID

Expiratory airflow limitation is the most obvious physiological change associated with chronic obstructive pulmonary disease (COPD). A consequence of airflow limitation is gas trapping as expiration becomes flow limited. This may occur at rest with more severe airway obstruction and is most evident during exercise as lung emptying is reduced and increased ventilation does not allow full expiration. This increased gas trapping or hyperinflation is the cause of much of the increased work of breathing, dyspnea, and exercise intolerance in subjects with COPD (O'Donnell 1997; O'Donnell, 1993). Spirometric measurement of airflow limitation, particularly as assessed by forced expiratory volume in one second (FEV1), is commonly used for the diagnosis of and assessment of response to pharmacotherapeutic intervention in COPD. However, changes in FEV1 may not fully predict symptomatic responses and alternative measures of lung hyperinflation such as exercise tolerance and exertional dyspnea may be more sensitive to therapeutic intervention and/or more clinically relevant than FEV1 [O'Donnell1999; Bauerle, 1998; O'Donnell, 1998; Officer, 1998]. GSK573719/GW642444 Inhalation Powder, a combination of the long-acting muscarinic antagonist (LAMA) bronchodilator GSK573719 and the long-acting beta2-agonist (LABA) bronchodilator GW642444, is in development for the maintenance treatment of airflow obstruction associated with COPD. Development of this product is supported by studies showing improvement in lung function with similar safety when use of combinations of long-acting bronchodilators with different mechanisms of action are compared with single bronchodilator therapy [van Noord

2005; van Noord van Noord 2006; Tashkin 2008]. Previous studies have demonstrated that treatment with short- and long-acting bronchodilators including ipratropium, tiotropium, and salmeterol reduces resting lung hyperinflation as measured by functional residual capacity (FRC), residual volume (RV), and inspiratory capacity (IC), with associated improvements in exercise endurance time and exertional dyspnoea in subjects with COPD [Ayers, 2001; O'Donnell 1998; O'Donnell 2004; Pepin 2005; Pepin 2007; Ramirez-Venegas 1997]. However, the effect of combined LAMA/LABA therapy on these measures is not well characterized.

This is a phase III multicenter, randomized, double-blind, placebo-controlled, combination and component, two-period, incomplete block design cross-over study using GSK573719/GW642444. The primary objective is to evaluate lung function and exercise endurance time after 12 weeks of once-daily administration of GSK573719/GW642444 Inhalation Powder (125/25mcg and 62.5/25mcg), GSK573719 Inhalation Powder (125mcg and 62.5mcg), GW642444 Inhalation Powder 25 mcg and placebo delivered by a Novel dry powder inhaler (Novel DPI) Approximately 312 subjects with moderate/severe chronic obstructive pulmonary disease (COPD) will be randomised in order to achieve 208 subjects completing both treatment periods of 3 months.. There will be a total of 12 study clinic visits conducted on an outpatient basis. Subjects who meet the eligibility criteria at Screening (Visit 1) will complete a 12 to 21 day run-in period followed by two 12-week treatment periods that are separated by a 14 day wash-out. Clinic visits will be conducted at Screening (Visit 1), twice during the run-in period (Visits 2 and 3), at randomization (Visit 4) and three times during the first treatment period, on Treatment Day 2 (Visit 5) and at 6 and 12 weeks (Visits 6 and 7 respectively). During the washout period of 14 days there will be 2 clinic visits (Visits 8 and 9). During the second treatment period there will be 3 clinic visits, on Treatment Day 2 (Visit 10) and at 6 and 12 weeks (Visits 11 and 12 respectively). A Safety Follow-Up assessment (Visit 13) to record adverse events will be conducted by telephone 7 days after the end of the second treatment period or early withdrawal. Efficacy measurements will include pre and post dose FEV1, lung volume measurements and exercise endurance time measured using the endurance shuttle walking test (ESWT). Safety and tolerability will be assessed by collection of adverse events (AEs), vital signs, 12-lead electrocardiograms (ECGs), clinical laboratory tests and incidence of COPD exacerbations. Dyspnea will be assessed using the Exercise Dyspnea Scale (EDS), a patient-reported outcome. Blood samples will also be collected for potential pharmacogenetics analysis

Eligibility

Ages Eligible for Study: 40 Years and older

Genders Eligible for Study: Male

Inclusion Criteria:

- Type of subject: Outpatient.
- Informed Consent: A signed and dated written informed consent prior to study participation.
- Age: 40 years of age or older at Visit 1.
- Gender: Male or female subjects.
- Diagnosis: An established clinical history of COPD in accordance with the definition by the American Thoracic Society/European Respiratory Society [Celli, 2004]
- Smoking History: Current or former cigarette smokers with a history of cigarette smoking of ≥ 10 pack-years
- Severity of Disease: A post-albuterol/salbutamol FEV1/FVC ratio of 0.70 and a post-albuterol/salbutamol FEV1 of $>35\%$ and $<70\%$ of predicted normal

- Dyspnea: A score of ≥ 2 on the Modified Medical Research Council Dyspnea Scale (mMRC) at Visit 1
- Resting Lung Volumes: A resting FRC of $\geq 120\%$ of predicted normal FRC at Visit 1.

Exclusion Criteria:

- Pregnancy: Women who are pregnant or lactating or are planning on becoming pregnant during the study.
- Asthma: A current diagnosis of asthma.
- Other Respiratory Disorders: Known respiratory disorders other than COPD including but not limited to alpha-1 antitrypsin deficiency, active tuberculosis, bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, and interstitial lung disease. Allergic rhinitis is not exclusionary.
- Other Diseases/Abnormalities: Subjects with historical or current evidence of clinically significant cardiovascular, neurological, psychiatric, renal, hepatic, immunological, endocrine (including uncontrolled diabetes or thyroid disease) or haematological abnormalities that are uncontrolled and/or a previous history of cancer in remission for < 5 years prior to Visit 1 (localized carcinoma of the skin that has been resected for cure is not exclusionary). Significant is defined as any disease that, in the opinion of the investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study. Any physical or mental abnormality which would affect the patient carrying out exercise tests including peripheral vascular disease should be excluded at the investigators discretion.
- Chest X-Ray: A chest X-ray or computed tomography (CT) scan that reveals evidence of clinically significant abnormalities not believed to be due to the presence of COPD. A chest X-ray must be taken at Visit 1 if a chest X-ray or CT scan is not available within 6 months prior to Visit 1. For subjects in Germany, if a chest X-ray (or CT scan) is not available in the 6 months prior to Visit 1 the subject will not be eligible for the study.
- Contraindications: A history of allergy or hypersensitivity to any anticholinergic/muscarinic receptor antagonist, beta2-agonist, lactose/milk protein or magnesium stearate or a medical condition such as narrow-angle glaucoma, prostatic hypertrophy or bladder neck obstruction that, in the opinion of the study physician contraindicates study participation or use of an inhaled anticholinergic.
- Hospitalization: Hospitalization for COPD or pneumonia within 12 weeks prior to Visit 1.
- Lung Resection: Subjects with lung volume reduction surgery within the 12 months prior to Screening (Visit 1).
- 12-Lead ECG: An abnormal and significant ECG finding from the 12-lead ECG conducted at Visit 1, including the presence of a paced rhythm on a 12-lead electrocardiogram (ECG) which causes the underlying rhythm and ECG to be obscured. Investigators will be provided with ECG reviews conducted by a centralized independent cardiologist to assist in evaluation of subject eligibility.
- Screening Labs: Significantly abnormal finding from clinical chemistry and hematology tests at Visit 1.
- Medication Prior to Spirometry: Unable to withhold albuterol/salbutamol for the 4 hour period required prior to spirometry testing at each study visit.
- Medications prior to Screening, including depot, oral corticosteroids, combinations of LABA/ICS, LABA, PDE4 inhibitors.
- Oxygen: Use of long-term oxygen therapy (LTOT) described as oxygen therapy prescribed for greater than 12 hours a day. As-needed oxygen use (i.e., < 12 hours per day) is not exclusionary.
- Nebulized Therapy: Regular use (prescribed for use every day, not for as-needed use) of short-acting bronchodilators (e.g., albuterol/salbutamol) via nebulized therapy
- Pulmonary Rehabilitation Program: Participation in the acute phase of a pulmonary rehabilitation program within 4 weeks prior to Visit 1. Subjects who are in the maintenance phase of a pulmonary rehabilitation program are not excluded.
- Drug or Alcohol Abuse: A known or suspected history of alcohol or drug abuse within 2 years prior to Visit 1.

- Affiliation with Investigator Site: Is an investigator, sub-investigator, study coordinator, employee of a participating investigator or study site, or immediate family member of the aforementioned that is involved in this study

Contacts and Locations

Locations

United States, Alabama

GSK Investigational Site

Jasper, Alabama, United States, 35501

United States, California

GSK Investigational Site

Torrance, California, United States, 90505

United States, Colorado

GSK Investigational Site

Fort Collins, Colorado, United States, 80528

United States, Connecticut

GSK Investigational Site

Hartford, Connecticut, United States, 06105

United States, Florida

GSK Investigational Site

Brandon, Florida, United States, 33511

United States, Georgia

GSK Investigational Site

Austell, Georgia, United States, 30106

GSK Investigational Site

Lawrenceville, Georgia, United States, 30046

United States, Kansas

GSK Investigational Site

Topeka, Kansas, United States, 66606

United States, Michigan

GSK Investigational Site

Livonia, Michigan, United States, 48152

United States, Missouri

GSK Investigational Site

St. Charles, Missouri, United States, 63301

GSK Investigational Site

St. Louis, Missouri, United States, 63141

United States, New Mexico

GSK Investigational Site

Albuquerque, New Mexico, United States, 87108

United States, North Carolina

GSK Investigational Site

Charlotte, North Carolina, United States, 28207

United States, South Carolina

GSK Investigational Site

Charleston, South Carolina, United States, 29406-7108

GSK Investigational Site

Easley, South Carolina, United States, 29640

United States, Texas

GSK Investigational Site

Austin, Texas, United States, 78758

GSK Investigational Site

The Woodlands, Texas, United States, 77380

United States, Virginia

GSK Investigational Site

Richmond, Virginia, United States, 23225

Canada, Ontario

GSK Investigational Site

Hamilton, Ontario, Canada, L8N 3Z5

GSK Investigational Site

Toronto, Ontario, Canada, M3H 5S4

GSK Investigational Site

Toronto, Ontario, Canada, M5T 3A9

Canada, Quebec

GSK Investigational Site

Montreal, Quebec, Canada, H2W 1T8
GSK Investigational Site
Quebec, Quebec, Canada, G1V 4G5

Czech Republic

GSK Investigational Site
Hradec Kralove, Czech Republic, 500 05
GSK Investigational Site
Karlovy Vary, Czech Republic, 360 09
GSK Investigational Site
Ostrava - Poruba, Czech Republic, 70868
GSK Investigational Site
Praha 4, Czech Republic, 14800
GSK Investigational Site
Praha 4, Czech Republic, 14059
GSK Investigational Site
Praha 4, Czech Republic
GSK Investigational Site
Teplice, Czech Republic, 415 10

Denmark

GSK Investigational Site
Aarhus C, Denmark, 8000
GSK Investigational Site
Hvidovre, Denmark, 2650
GSK Investigational Site
Kobenhavn NV, Denmark, 2400
GSK Investigational Site
Odense C, Denmark, 5000

South Africa

GSK Investigational Site
Bloemfontein, South Africa, 9301
GSK Investigational Site
Gatesville, South Africa, 7764
GSK Investigational Site
Groenkloof, South Africa, 0181

GSK Investigational Site
Mowbray, South Africa, 7700
GSK Investigational Site
Panorama, South Africa, 7500
GSK Investigational Site
George, Eastern Cape, South Africa, 6529

Ukraine

GSK Investigational Site
Donetsk, Ukraine, 83003
GSK Investigational Site
Kiev, Ukraine, 03680
GSK Investigational Site
Kyiv, Ukraine, 03680
GSK Investigational Site
Kyiv, Ukraine, 03115

United Kingdom

GSK Investigational Site
Birmingham, United Kingdom, B9 5SS
GSK Investigational Site
Bradford, United Kingdom, BD9 6RJ
GSK Investigational Site
Cottingham, East Yorkshire, United Kingdom, HU16 5JQ
GSK Investigational Site
Doncaster, United Kingdom, DN2 5LT
GSK Investigational Site
Glasgow, United Kingdom, G11 6NT
GSK Investigational Site
Somerset, United Kingdom, TA1 5DA
GSK Investigational Site
Wolverhampton, United Kingdom, WV10 00B
GSK Investigational Site
Leicester, Leicestershire, United Kingdom, LE3 9QP
GSK Investigational Site
Northwood, Middlesex, United Kingdom, HA6 2RN

Investigators

Study Director:

GSK Clinical Trials

GlaxoSmithKline

▶ More Information

Responsible Party: GlaxoSmithKline

Study ID Numbers: 114418

Health Authority: United States: Food and Drug Administration

Study Results

▶ Participant Flow

Recruitment Details

Participants (par.) who were eligible completed a 12- to 21-day Run-in Period followed by two 12-week treatment (trt) periods.

Pre-Assignment Details

A total of 634 par. were enrolled and screened, 393 par. entered the Run-in Period, 308 par. were randomized and 307 par. received study trt. Participant Flow data are presented by treatment rather than sequence. Par. received 2 out of the 6 interventions.

Reporting Groups

	Description
Placebo	Participants received matching placebo once daily (QD) via a dry powder inhaler (DPI) in the morning for 12weeks.
UMEC 62.5 µg QD	Participants received umeclidinium bromide (UMEC) 62.5 micrograms (µg) QD via a DPI in the morning for 12 weeks.
UMEC 125 µg QD	Participants received UMEC 125 µg QD via a DPI in the morning for 12 weeks.

	Description
VI 25 µg QD	Participants received vilanterol (VI) 25 µg QD via a DPI for 12 weeks.
UMEC/VI 62.5/25 µg QD	Participants received UMEC/VI 62.5/25 µg QD via a DPI in the morning for 12 weeks.
UMEC 125/25 µg QD	Participants received UMEC/VI 125/25 µg QD via a DPI in the morning for 12 weeks.

Treatment Period 1 (12 Weeks)

	Placebo	UMEC 62.5 µg QD	UMEC 125 µg QD	VI 25 µg QD	UMEC/VI 62.5/25 µg QD	UMEC 125/25 µg QD
Started	84	22	24	36	71	70
Completed	65	21	19	31	61	61
Not Completed	19	1	5	5	10	9
Adverse Event	6	1	1	3	3	4
Lack of Efficacy	6	0	2	0	1	3
Protocol Violation	2	0	1	1	1	2
Met Protocol-defined Stopping Criteria	0	0	0	0	1	0
Lost to Follow-up	0	0	0	0	1	0
Withdrawal by Subject	5	0	1	1	3	0

Washout Period (14 Days)

	Placebo	UMEC 62.5 µg QD	UMEC 125 µg QD	VI 25 µg QD	UMEC/VI 62.5/25 µg QD	UMEC 125/25 µg QD
Started	65	21	19	31	61	61
Completed	65 ^[1]	21 ^[2]	18 ^[3]	28 ^[4]	58 ^[5]	59 ^[6]
Not Completed	0	0	1	3	3	2
Adverse Event	0	0	0	0	1	0
Lack of Efficacy	0	0	1	3	2	2

[1] Participants withdrawing during washout are counted under the last treatment taken.

[2] Participants withdrawing during washout are counted under the last treatment taken.

[3] Participants withdrawing during washout are counted under the last treatment taken.

[4] Participants withdrawing during washout are counted under the last treatment taken.

[5] Participants withdrawing during washout are counted under the last treatment taken.

[6] Participants withdrawing during washout are counted under the last treatment taken.

Treatment Period 2 (12 Weeks)

	Placebo	UMEC 62.5 µg QD	UMEC 125 µg QD	VI 25 µg QD	UMEC/VI 62.5/25 µg QD	UMEC 125/25 µg QD
Started	67 ^[1]	18 ^[2]	17 ^[3]	28 ^[4]	59 ^[5]	58 ^[6]
Completed	55	17	14	25	55	51
Not Completed	12	1	3	3	4	7
Adverse Event	1	0	0	1	1	2
Lack of Efficacy	9	0	2	2	1	3
Study Closed/Terminated	0	0	0	0	0	1

	Placebo	UMEC 62.5 µg QD	UMEC 125 µg QD	VI 25 µg QD	UMEC/VI 62.5/25 µg QD	UMEC 125/25 µg QD
Lost to Follow-up	1	0	0	0	0	1
Withdrawal by Subject	1	1	1	0	2	0

[1] “By crossover design, participants were assigned to a different treatment arm in each period.

[2] “By crossover design, participants were assigned to a different treatment arm in each period.

[3] “By crossover design, participants were assigned to a different treatment arm in each period.

[4] “By crossover design, participants were assigned to a different treatment arm in each period.

[5] “By crossover design, participants were assigned to a different treatment arm in each period.

[6] “By crossover design, participants were assigned to a different treatment arm in each period.

► Baseline Characteristics

Reporting Groups

	Description
All Study Treatments	Participants were randomized to receive a sequence consisting of 2 of the following treatments: UMEC/VI 125/25 µg , UMEC/VI 62.5/25 µg , UMEC 125 µg , UMEC 62.5 µg , VI 25 µg , or placebo QD via a DPI. Each treatment was administered in the morning for 12 weeks. The treatment periods were separated by 14-day washout period.

Baseline Measures

	All Study Treatments
Number of Participants	307
Age, Continuous	62.6 (7.88)

	All Study Treatments
[units: Years] Mean (Standard Deviation)	
Gender, Male/Female [units: Participants]	
Female	139
Male	168
Race/Ethnicity, Customized [units: Participants]	
African American/African Heritage	6
American Indian or Alaska Native	1
Asian - South East Asian Heritage	1
White - White/Caucasian/European Heritage	298
Mixed Race	1

Outcome Measures

1. Primary Outcome Measure:

Measure Title	Change From Baseline in Exercise Endurance Time Post-dose at Week 12 of Each Treatment Period
Measure Description	Exercise endurance time (EET) post-dose at Week 12 is defined as the

	EET obtained 3 hours after dosing at Week 12. EET was measured using the externally paced field walking test called the endurance shuttle walk test (ESWT). Analysis performed using a repeated measures model with covariates of period walking speed, mean walking speed, period, treatment, visit, smoking status, center group, visit by period walking speed, visit by mean walking speed and visit by treatment interactions. The model used all available 3-hour post-dose change from baseline EET values recorded on Day 2, Week 6 and Week 12. Baseline was the EET assessment obtained prior to dosing on Day 1 of each period. The mean walking speed for each participant is the mean of the levels used for the ESWT in each of the two treatment periods. The period walking speed for each participant and treatment period is the difference between the level for that participant and period and the mean walking speed for that participant.
Time Frame	Week 12 of each treatment period (up to Study Week 30)
Safety Issue?	No

Analysis Population Description

Intent-to-Treat (ITT) Population: all par. randomized to treatment who received at least one dose of study drug in either treatment period. Number of par. represent those with data available at the time point; however, all par. in the ITT population without missing covariate information and with at least one post Baseline measurement are included.

Reporting Groups

	Description
Placebo	Participants received matching placebo QD via a DPI in the morning for 12 weeks.
UMEC 62.5 µg QD	Participants received UMEC 62.5 µg QD via a DPI in the morning for 12 weeks.
UMEC 125 µg QD	Participants received UMEC 125 µg QD via a DPI in the morning for 12 weeks.

	Description
VI 25 µg QD	Participants received VI 25 µg QD via a DPI for 12 weeks.
UMEC/VI 62.5/25 µg QD	Participants received UMEC/VI 62.5/25 µg QD via a DPI in the morning for 12 weeks.
UMEC/VI 125/25 µg QD	Participants received UMEC/VI 125/25 µg QD via a DPI in the morning for 12 weeks.

Measured Values

	Placebo	UMEC 62.5 µg QD	UMEC 125 µg QD	VI 25 µg QD	UMEC/VI 62.5/25 µg QD	UMEC/VI 125/25 µg QD
Number of Participants Analyzed	117	37	32	54	115	109
Change From Baseline in Exercise Endurance Time Post-dose at Week 12 of Each Treatment Period [units: Seconds] Least Squares Mean (Standard Error)	0.1 (16.66)	25.1 (30.18)	74.8 (31.58)	30.7 (24.79)	69.5 (17.09)	65.9 (17.48)

Statistical Analysis 1 for Change From Baseline in Exercise Endurance Time Post-dose at Week 12 of Each Treatment Period

Groups	Placebo, UMEC 62.5 µg QD
Method	Mixed Models Analysis
P-Value	0.456
Other Estimated Parameter [Least squares mean difference]	25.0
95% Confidence Interval	-41.0 to 91.0

Additional details about the analysis, such as null hypothesis and power calculation:

[Not specified.]

Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:

Nominal p-value

Other relevant information, such as adjustments or degrees of freedom:

Restricted maximum likelihood (REML)-based repeated measures approach (MMRM).

Other relevant estimation information:

Least square mean change difference=UMEC 62.5 µg minus Placebo.

Statistical Analysis 2 for Change From Baseline in Exercise Endurance Time Post-dose at Week 12 of Each Treatment Period

Groups	Placebo, UMEC 125 µg QD
Method	Mixed Models Analysis
P-Value	0.033
Other Estimated Parameter [Least squares mean difference]	74.7
95% Confidence Interval	6.0 to 143.4

Additional details about the analysis, such as null hypothesis and power calculation:

[Not specified.]

Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:

Nominal p-value

Other relevant information, such as adjustments or degrees of freedom:

Restricted maximum likelihood (REML)-based repeated measures approach (MMRM).

Other relevant estimation information:

Least square mean change difference=UMEC 125 µg minus Placebo.

Statistical Analysis 3 for Change From Baseline in Exercise Endurance Time Post-dose at Week 12 of Each Treatment Period

Groups	Placebo, VI 25 µg QD
Method	Mixed Models Analysis
P-Value	0.295
Other Estimated Parameter [Least squares mean difference]	30.6
95% Confidence Interval	-26.8 to 88.0

Additional details about the analysis, such as null hypothesis and power calculation:

[Not specified.]

Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:

Nominal p-value

Other relevant information, such as adjustments or degrees of freedom:

Restricted maximum likelihood (REML)-based repeated measures approach (MMRM).

Other relevant estimation information:

Least square mean change difference=VI 25 µg minus Placebo.

Statistical Analysis 4 for Change From Baseline in Exercise Endurance Time Post-dose at Week 12 of Each Treatment Period

Groups	UMEC 62.5 µg QD, UMEC/VI 62.5/25 µg QD
Method	Mixed Models Analysis
P-Value	0.188
Other Estimated Parameter [Least squares mean difference]	44.4
95% Confidence Interval	-21.8 to 110.6

Additional details about the analysis, such as null hypothesis and power calculation:

[Not specified.]

Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:

Nominal p-value

Other relevant information, such as adjustments or degrees of freedom:

Restricted maximum likelihood (REML)-based repeated measures approach (MMRM).

Other relevant estimation information:

Least square mean change difference=UMEC/VI 62.5/25 µg minus UMEC 62.5 µg.

Statistical Analysis 5 for Change From Baseline in Exercise Endurance Time Post-dose at Week 12 of Each Treatment Period

Groups	VI 25 µg QD, UMEC/VI 62.5/25 µg QD
Method	Mixed Models Analysis
P-Value	0.187
Other Estimated Parameter [Least squares mean difference]	38.8
95% Confidence Interval	-18.9 to 96.5

Additional details about the analysis, such as null hypothesis and power calculation:

[Not specified.]

Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:

Nominal p-value

Other relevant information, such as adjustments or degrees of freedom:

Restricted maximum likelihood (REML)-based repeated measures approach (MMRM).

Other relevant estimation information:

Least square mean change difference=UMEC/VI 62.5/25 µg minus VI 25 µg.

Statistical Analysis 6 for Change From Baseline in Exercise Endurance Time Post-dose at Week 12 of Each Treatment Period

Groups	UMEC 125 µg QD, UMEC/VI 125/25 µg QD
--------	--------------------------------------

Method	Mixed Models Analysis
P-Value	0.801
Other Estimated Parameter [Least squares mean difference]	-8.9
95% Confidence Interval	-77.8 to 60.1

Additional details about the analysis, such as null hypothesis and power calculation:

[Not specified.]

Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:

Nominal p-value

Other relevant information, such as adjustments or degrees of freedom:

Restricted maximum likelihood (REML)-based repeated measures approach (MMRM).

Other relevant estimation information:

Least square mean change difference=UMEC/VI 125/25 µg minus UMEC 125 µg

Statistical Analysis 7 for Change From Baseline in Exercise Endurance Time Post-dose at Week 12 of Each Treatment Period

Groups	VI 25 µg QD, UMEC/VI 125/25 µg QD
Method	Mixed Models Analysis
P-Value	0.233
Other Estimated Parameter [Least squares mean difference]	35.2
95% Confidence Interval	-22.7 to 93.1

Additional details about the analysis, such as null hypothesis and power calculation:

[Not specified.]

Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for

statistical significance:

Nominal p-value

Other relevant information, such as adjustments or degrees of freedom:

Restricted maximum likelihood (REML)-based repeated measures approach (MMRM).

Other relevant estimation information:

Least square mean change difference=UMEC/VI 125/25 µg minus VI 25 µg.

Statistical Analysis 8 for Change From Baseline in Exercise Endurance Time Post-dose at Week 12 of Each Treatment Period

Groups	Placebo, UMEC/VI 62.5/25 µg QD
Method	Mixed Models Analysis
P-Value	0.003
Other Estimated Parameter [Least squares mean difference]	69.4
95% Confidence Interval	24.5 to 114.4

Additional details about the analysis, such as null hypothesis and power calculation:

[Not specified.]

Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:

[Not specified.]

Other relevant information, such as adjustments or degrees of freedom:

Restricted maximum likelihood (REML)-based repeated measures approach (MMRM).

Other relevant estimation information:

Least square mean change difference=UMEC/VI 62.5/25 µg minus Placebo.

Statistical Analysis 9 for Change From Baseline in Exercise Endurance Time Post-dose at Week 12 of Each Treatment Period

Groups	Placebo, UMEC/VI 125/25 µg QD
Method	Mixed Models Analysis

P-Value	0.005
Other Estimated Parameter [Least squares mean difference]	65.8
95% Confidence Interval	20.3 to 111.3

Additional details about the analysis, such as null hypothesis and power calculation:

[Not specified.]

Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:

[Not specified.]

Other relevant information, such as adjustments or degrees of freedom:

Restricted maximum likelihood (REML)-based repeated measures approach (MMRM).

Other relevant estimation information:

Least square mean change difference=UMEC/VI 125/25 µg minus Placebo.

2. Primary Outcome Measure:

Measure Title	Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at Week 12 of Each Treatment Period
Measure Description	FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 measurements were taken electronically by spirometry on Day 2, Week 6 and Week 12. Baseline is the FEV1 value recorded pre-dose on Day 1 of each treatment period, mean Baseline is the mean of the Baselines for each participant, and period Baseline is the difference between the Baseline and the mean Baseline in each treatment period for each participant. Clinic visit trough (pre-bronchodilator and pre-dose) FEV1 at Week 12 (Treatment Day 85) is defined as the FEV1 value obtained 24 hours after dosing on Treatment Day 84.

	Analysis performed using a repeated measures model with covariates of period Baseline, mean Baseline, period, treatment, visit, smoking status, center group, visit by period Baseline, visit by mean Baseline and visit by treatment interactions.
Time Frame	Week 12 of each treatment period (up to Study Week 30)
Safety Issue?	No

Analysis Population Description

Intent-to-Treat (ITT) Population: all par. randomized to treatment who received at least one dose of study drug in either treatment period. Number of par. represent those with data available at the time point; however, all par. in the ITT population without missing covariate information and with at least one post Baseline measurement are included.

Reporting Groups

	Description
Placebo	Participants received matching placebo QD via a DPI in the morning for 12 weeks.
UMEC 62.5 µg QD	Participants received UMEC 62.5 µg QD via a DPI in the morning for 12 weeks.
UMEC 125 µg QD	Participants received UMEC 125 µg QD via a DPI in the morning for 12 weeks.
VI 25 µg QD	Participants received VI 25 µg QD via a DPI for 12 weeks.
UMEC/VI 62.5/25 µg QD	Participants received UMEC/VI 62.5/25 µg QD via a DPI in the morning for 12 weeks.
UMEC/VI 125/25 µg QD	Participants received UMEC/VI 125/25 µg QD via a DPI in the morning for 12 weeks.

Measured Values

	Placebo	UMEC 62.5 µg QD	UMEC 125 µg QD	VI 25 µg QD	UMEC/VI 62.5/25 µg QD	UMEC/VI 125/25 µg QD
Number of Participants Analyzed	119	38	33	56	117	112
Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at Week 12 of Each Treatment Period [units: Liters] Least Squares Mean (Standard Error)	-0.043 (0.0156)	0.101 (0.0267)	0.212 (0.0287)	0.069 (0.0222)	0.200 (0.0156)	0.218 (0.0159)

Statistical Analysis 1 for Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at Week 12 of Each Treatment Period

Groups	Placebo, UMEC 62.5 µg QD
Method	Mixed Models Analysis
P-Value	<0.001
Other Estimated Parameter [Least squares mean difference]	0.144
95% Confidence Interval	0.086 to 0.203

Additional details about the analysis, such as null hypothesis and power calculation:

[Not specified.]

Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:

[Not specified.]

Other relevant information, such as adjustments or degrees of freedom:

Restricted maximum likelihood (REML)-based repeated measures approach (MMRM).

Other relevant estimation information:

Least square mean change difference=UMEC 62.5 µg minus Placebo.

Statistical Analysis 2 for Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at Week 12 of Each Treatment Period

Groups	Placebo, UMEC 125 µg QD
Method	Mixed Models Analysis
P-Value	<0.001
Other Estimated Parameter [Least squares mean difference]	0.255
95% Confidence Interval	0.193 to 0.318

Additional details about the analysis, such as null hypothesis and power calculation:

[Not specified.]

Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:

[Not specified.]

Other relevant information, such as adjustments or degrees of freedom:

Restricted maximum likelihood (REML)-based repeated measures approach (MMRM).

Other relevant estimation information:

Least square mean change difference=UMEC 125 µg minus Placebo.

Statistical Analysis 3 for Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at Week 12 of Each Treatment Period

Groups	Placebo, VI 25 µg QD
Method	Mixed Models Analysis
P-Value	<0.001
Other Estimated Parameter [Least squares mean difference]	0.112
95% Confidence Interval	0.061 to 0.163

Additional details about the analysis, such as null hypothesis and power calculation:

[Not specified.]

Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:

[Not specified.]

Other relevant information, such as adjustments or degrees of freedom:

Restricted maximum likelihood (REML)-based repeated measures approach (MMRM).

Other relevant estimation information:

Least square mean change difference=VI 25 µg minus Placebo.

Statistical Analysis 4 for Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at Week 12 of Each Treatment Period

Groups	UMEC 62.5 µg QD, UMEC/VI 62.5/25 µg QD
Method	Mixed Models Analysis
P-Value	<0.001
Other Estimated Parameter [Least squares mean difference]	0.099
95% Confidence Interval	0.041 to 0.157

Additional details about the analysis, such as null hypothesis and power calculation:

[Not specified.]

Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:

[Not specified.]

Other relevant information, such as adjustments or degrees of freedom:

Restricted maximum likelihood (REML)-based repeated measures approach (MMRM).

Other relevant estimation information:

Least square mean change difference=UMEC/VI 62.5/25 µg minus UMEC 62.5 µg.

Statistical Analysis 5 for Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at Week 12 of Each Treatment Period

Groups	VI 25 µg QD, UMEC/VI 62.5/25 µg QD
Method	Mixed Models Analysis
P-Value	<0.001
Other Estimated Parameter [Least squares mean difference]	0.132
95% Confidence Interval	0.081 to 0.183

Additional details about the analysis, such as null hypothesis and power calculation:

[Not specified.]

Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:

[Not specified.]

Other relevant information, such as adjustments or degrees of freedom:

Restricted maximum likelihood (REML)-based repeated measures approach (MMRM).

Other relevant estimation information:

Least square mean change difference=UMEC/VI 62.5/25 µg minus VI 25 µg.

Statistical Analysis 6 for Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at Week 12 of Each Treatment Period

Groups	UMEC 125 µg QD, UMEC/VI 125/25 µg QD
Method	Mixed Models Analysis
P-Value	0.849
Other Estimated Parameter [Least squares mean difference]	0.006
95% Confidence Interval	-0.055 to 0.067

Additional details about the analysis, such as null hypothesis and power calculation:

[Not specified.]

Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:

[Not specified.]

Other relevant information, such as adjustments or degrees of freedom:

Restricted maximum likelihood (REML)-based repeated measures approach (MMRM).

Other relevant estimation information:

Least square mean change difference=UMEC/VI 125/25 µg minus UMEC 125 µg.

Statistical Analysis 7 for Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at Week 12 of Each Treatment Period

Groups	VI 25 µg QD, UMEC/VI 125/25 µg QD
Method	Mixed Models Analysis
P-Value	<0.001
Other Estimated Parameter [Least squares mean difference]	0.150
95% Confidence Interval	0.098 to 0.201

Additional details about the analysis, such as null hypothesis and power calculation:

[Not specified.]

Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:

[Not specified.]

Other relevant information, such as adjustments or degrees of freedom:

Restricted maximum likelihood (REML)-based repeated measures approach (MMRM).

Other relevant estimation information:

Least square mean change difference=UMEC/VI 125/25 µg minus VI 25 µg.

Statistical Analysis 8 for Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at Week 12 of Each Treatment Period

Groups	Placebo, UMEC/VI 62.5/25 µg QD
Method	Mixed Models Analysis
P-Value	<0.001
Other Estimated Parameter [Least squares mean difference]	0.243
95% Confidence Interval	0.202 to 0.284

Additional details about the analysis, such as null hypothesis and power calculation:

[Not specified.]

Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:

[Not specified.]

Other relevant information, such as adjustments or degrees of freedom:

Restricted maximum likelihood (REML)-based repeated measures approach (MMRM).

Other relevant estimation information:

Least square mean change difference=UMEC/VI 62.5/25 µg minus Placebo.

Statistical Analysis 9 for Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at Week 12 of Each Treatment Period

Groups	Placebo, UMEC/VI 125/25 µg QD
Method	Mixed Models Analysis
P-Value	<0.001
Other Estimated Parameter [Least squares mean difference]	0.261
95% Confidence Interval	0.220 to 0.303

Additional details about the analysis, such as null hypothesis and power calculation:

[Not specified.]

Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:

[Not specified.]

Other relevant information, such as adjustments or degrees of freedom:

Restricted maximum likelihood (REML)-based repeated measures approach (MMRM).

Other relevant estimation information:

Least square mean change difference=UMEC/VI 125/25 µg minus Placebo.

3. Secondary Outcome Measure:

Measure Title	Change From Baseline in Inspiratory Capacity (Trough and 3-hours Post-dose) at Week 12 of Each Treatment Period
Measure Description	Inspiratory capacity (IC) is defined as the maximum amount of air that can be inhaled into the lungs from the normal resting position after breathing out normally. Baseline is the IC value recorded pre-dose on Day 1 of each treatment period, mean Baseline is the mean of the Baselines for each participant, and period Baseline is the difference between the Baseline and the mean Baseline in each treatment period for each participant. Trough IC is measured pre-dose on Treatment Week 12 of each treatment period. IC 3-hours post-dose is measured from the value obtained 3 hours after dosing on Treatment Week 12 of each treatment period. Analysis performed using a repeated measures model with covariates of period Baseline, mean Baseline, period, treatment, visit, smoking status, center group, visit by period Baseline, visit by mean Baseline and visit by treatment interactions. IC measurements were taken electronically by plethysmography on Day 2, Week 6 and Week 12.
Time Frame	Week 12 of each treatment period (up to Study Week 30)

Safety Issue?	No
---------------	----

Analysis Population Description

Intent-to-Treat (ITT) population: all par. randomized to treatment who received at least one dose of study drug in either treatment period. Number of par. represent those with data available at the time point; however, all par. in the ITT population without missing covariate information and with at least one post Baseline measurement are included.

Reporting Groups

	Description
Placebo	Participants received matching placebo QD via a DPI in the morning for 12 weeks.
UMEC 62.5 µg QD	Participants received UMEC 62.5 µg QD via a DPI in the morning for 12 weeks.
UMEC 125 µg QD	Participants received UMEC 125 µg QD via a DPI in the morning for 12 weeks.
VI 25 µg QD	Participants received VI 25 µg QD via a DPI for 12 weeks.
UMEC/VI 62.5/25 µg QD	Participants received UMEC/VI 62.5/25 µg QD via a DPI in the morning for 12 weeks.
UMEC/VI 125/25 µg QD	Participants received UMEC/VI 125/25 µg QD via a DPI in the morning for 12 weeks.

Measured Values

	Placebo	UMEC 62.5 µg QD	UMEC 125 µg QD	VI 25 µg QD	UMEC/VI 62.5/25 µg QD	UMEC/VI 125/25 µg QD
Number of Participants Analyzed	120	38	33	56	117	111
Change From Baseline in Inspiratory						

	Placebo	UMEC 62.5 µg QD	UMEC 125 µg QD	VI 25 µg QD	UMEC/VI 62.5/25 µg QD	UMEC/VI 125/25 µg QD
Capacity (Trough and 3-hours Post-dose) at Week 12 of Each Treatment Period [units: Liters] Least Squares Mean (Standard Error)						
Trough	-0.021 (0.0271)	0.077 (0.0471)	0.216 (0.0505)	0.081 (0.0391)	0.216 (0.0274)	0.204 (0.0281)
3-hours post-dose	-0.021 (0.0273)	0.155 (0.0465)	0.208 (0.0498)	0.156 (0.0389)	0.295 (0.0276)	0.312 (0.0283)

4. Secondary Outcome Measure:

Measure Title	Change From Baseline in Functional Residual Capacity (Trough and 3-hours Post-dose) at Week 12 of Each Treatment Period
Measure Description	Functional Residual Capacity (FRC) is defined as the amount of air still left in the lungs after breathing out normally. Baseline is the FRC value recorded pre-dose on Day 1 of each treatment period, mean Baseline is the mean of the Baselines for each participant, and period Baseline is the difference between the Baseline and the mean Baseline in each treatment period for each participant. Trough FRC is measured pre-dose on Treatment Week 12. FRC 3-hours post-dose is measured from the value obtained 3 hours after dosing on Treatment Week 12. Analysis performed using a repeated measures model with covariates of period Baseline, mean Baseline, period, treatment, visit, smoking status, center group, visit by period Baseline, visit by mean Baseline and visit by treatment interactions. FRC measurements were taken electronically by plethysmography on Day 2, Week 6 and Week 12.
Time Frame	Week 12 of each treatment period (up to Study Week 30)

Safety Issue?	No
---------------	----

Analysis Population Description

Intent-to-Treat (ITT) population: all par. randomized to treatment who received at least one dose of study drug in either treatment period. Number of par. represent those with data available at the time point; however, all par. in the ITT population without missing covariate information and with at least one post Baseline measurement are included.

Reporting Groups

	Description
Placebo	Participants received matching placebo QD via a DPI in the morning for 12 weeks.
UMEC 62.5 µg QD	Participants received UMEC 62.5 µg QD via a DPI in the morning for 12 weeks.
UMEC 125 µg QD	Participants received UMEC 125 µg QD via a DPI in the morning for 12 weeks.
VI 25 µg QD	Participants received VI 25 µg QD via a DPI for 12 weeks.
UMEC/VI 62.5/25 µg QD	Participants received UMEC/VI 62.5/25 µg QD via a DPI in the morning for 12 weeks.
UMEC/VI 125/25 µg QD	Participants received UMEC/VI 125/25 µg QD via a DPI in the morning for 12 weeks.

Measured Values

	Placebo	UMEC 62.5 µg QD	UMEC 125 µg QD	VI 25 µg QD	UMEC/VI 62.5/25 µg QD	UMEC/VI 125/25 µg QD
Number of Participants Analyzed	120	38	33	56	117	111
Change From Baseline in Functional						

	Placebo	UMEC 62.5 µg QD	UMEC 125 µg QD	VI 25 µg QD	UMEC/VI 62.5/25 µg QD	UMEC/VI 125/25 µg QD
Residual Capacity (Trough and 3-hours Post-dose) at Week 12 of Each Treatment Period [units: Liters] Least Squares Mean (Standard Error)						
Trough	-0.083 (0.0460)	-0.200 (0.0804)	-0.263 (0.0862)	-0.218 (0.0666)	-0.434 (0.0469)	-0.333 (0.0480)
3-hours post-dose	-0.094 (0.0461)	-0.315 (0.0786)	-0.405 (0.0836)	-0.431 (0.0654)	-0.616 (0.0471)	-0.503 (0.0480)

5. Secondary Outcome Measure:

Measure Title	Change From Baseline in Residual Volume (Trough and 3-hours Post-dose) at Week 12 of Each Treatment Period
Measure Description	Residual Volume (RV) is defined as the air that remains in the lungs after breathing out as fully as possible. Baseline is the RV value recorded pre-dose on Day 1 of each treatment period, mean Baseline is the mean of the Baselines for each participant, and period Baseline is the difference between the Baseline and the mean Baseline in each treatment period for each participant. Trough RV is measured pre-dose on Treatment Week 12. RV 3-hours post-dose is measured from the value obtained 3 hours after dosing on Treatment Week 12. Analysis performed using a repeated measures model with covariates of period Baseline, mean Baseline, period, treatment, visit, smoking status, center group, visit by period Baseline, visit by mean Baseline and visit by treatment interactions. RV measurements were taken electronically by plethysmography on Day 2, Week 6 and Week 1.
Time Frame	Week 12 of each treatment period (up to Study Week 30)

Safety Issue?	No
---------------	----

Analysis Population Description

Intent-to-Treat (ITT) population: all par. randomized to treatment who received at least one dose of study drug in either treatment period. Number of par. represent those with data available at the time point; however, all par. in the ITT population without missing covariate information and with at least one post Baseline measurement are included.

Reporting Groups

	Description
Placebo	Participants received matching placebo QD via a DPI in the morning for 12 weeks.
UMEC 62.5 µg QD	Participants received UMEC 62.5 µg QD via a DPI in the morning for 12 weeks.
UMEC 125 µg QD	Participants received UMEC 125 µg QD via a DPI in the morning for 12 weeks.
VI 25 µg QD	Participants received VI 25 µg QD via a DPI for 12 weeks.
UMEC/VI 62.5/25 µg QD	Participants received UMEC/VI 62.5/25 µg QD via a DPI in the morning for 12 weeks.
UMEC/VI 125/25 µg QD	Participants received UMEC/VI 125/25 µg QD via a DPI in the morning for 12 weeks.

Measured Values

	Placebo	UMEC 62.5 µg QD	UMEC 125 µg QD	VI 25 µg QD	UMEC/VI 62.5/25 µg QD	UMEC/VI 125/25 µg QD
Number of Participants Analyzed	120	38	33	56	117	111
Change From Baseline in Residual						

	Placebo	UMEC 62.5 µg QD	UMEC 125 µg QD	VI 25 µg QD	UMEC/VI 62.5/25 µg QD	UMEC/VI 125/25 µg QD
Volume (Trough and 3-hours Post-dose) at Week 12 of Each Treatment Period [units: Liters] Least Squares Mean (Standard Error)						
Trough	-0.049 (0.0491)	-0.266 (0.0847)	-0.289 (0.0909)	-0.291 (0.0705)	-0.516 (0.0500)	-0.421 (0.0511)
3-hours post-dose	-0.071 (0.0495)	-0.451 (0.0855)	-0.534 (0.0911)	-0.483 (0.0711)	-0.714 (0.0505)	-0.566 (0.0516)

6. Secondary Outcome Measure:

Measure Title	Change From Baseline in 3-hours Post-dose FEV1 at Week 12 of Each Treatment Period
Measure Description	FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Baseline is the FEV1 value recorded pre-dose on Day 1 of each treatment period, mean Baseline is the mean of the Baselines for each participant, and period Baseline is the difference between the Baseline and the mean Baseline in each treatment period for each participant. Clinic visit post-dose FEV1 at Week 12 (Treatment Day 85) is defined as the FEV1 value obtained 3 hours after dosing on Treatment Day 85. Analysis performed using a repeated measures model with covariates of period Baseline, mean Baseline, period, treatment, visit, smoking status, center group, visit by period Baseline, visit by mean Baseline and visit by treatment interactions 3 hour post-dose FEV1 measurements were taken electronically by spirometry on Day 2, Week 6 and Week 12.
Time Frame	Week 12 of each treatment period (up to Study Week 30)

Safety Issue?	No
---------------	----

Analysis Population Description

Intent-to-Treat (ITT) population: all par. randomized to treatment who received at least one dose of study drug in either treatment period. Number of par. represent those with data available at the time point; however, all par. in the ITT population without missing covariate information and with at least one post Baseline measurement are included.

Reporting Groups

	Description
Placebo	Participants received matching placebo QD via a DPI in the morning for 12 weeks.
UMEC 62.5 µg QD	Participants received UMEC 62.5 µg QD via a DPI in the morning for 12 weeks.
UMEC 125 µg QD	Participants received UMEC 125 µg QD via a DPI in the morning for 12 weeks.
VI 25 µg QD	Participants received VI 25 µg QD via a DPI for 12 weeks.
UMEC/VI 62.5/25 µg QD	Participants received UMEC/VI 62.5/25 µg QD via a DPI in the morning for 12 weeks.
UMEC/VI 125/25 µg QD	Participants received UMEC/VI 125/25 µg QD via a DPI in the morning for 12 weeks.

Measured Values

	Placebo	UMEC 62.5 µg QD	UMEC 125 µg QD	VI 25 µg QD	UMEC/VI 62.5/25 µg QD	UMEC/VI 125/25 µg QD
Number of Participants Analyzed	120	38	33	56	117	110
Change From Baseline in 3-hours	-0.019	0.168	0.215	0.143	0.297	0.343

	Placebo	UMEC 62.5 µg QD	UMEC 125 µg QD	VI 25 µg QD	UMEC/VI 62.5/25 µg QD	UMEC/VI 125/25 µg QD
Post-dose FEV1 at Week 12 of Each Treatment Period [units: Liters] Least Squares Mean (Standard Error)	(0.0175)	(0.0296)	(0.0317)	(0.0246)	(0.0175)	(0.0179)

Reported Adverse Events

Reporting Groups

	Description
Placebo	Participants received matching placebo QD via a DPI in the morning for 12 weeks.
UMEC 62.5 µg QD	Participants received UMEC 62.5 µg QD via a DPI in the morning for 12 weeks.
UMEC 125 µg QD	Participants received UMEC 125 µg QD via a DPI in the morning for 12 weeks.
VI 25 µg QD	Participants received VI 25 µg QD via a DPI for 12 weeks.
UMEC/VI 62.5/25 µg QD	Participants received UMEC/VI 62.5/25 µg QD via a DPI in the morning for 12 weeks.
UMEC/VI 125/25 µg QD	Participants received UMEC/VI 125/25 µg QD via a DPI in the morning for 12 weeks.

Time Frame

On-treatment serious adverse events (SAEs) and non-serious adverse events (AEs), defined as those events occurring while

participants were on treatment up until one day after the last dose (up to Week 33), are reported.

Additional Description

SAEs and non-serious AEs were reported for members of the Intent-to-Treat (ITT) Population, comprised of all participants randomized to treatment who received at least one dose of trial medication during the treatment period.

Serious Adverse Events

	Placebo	UMEC 62.5 µg QD	UMEC 125 µg QD	VI 25 µg QD	UMEC/VI 62.5/25 µg QD	UMEC/VI 125/25 µg QD
Total # participants affected/at risk	4/151 (2.65%)	1/40 (2.5%)	1/41 (2.44%)	2/64 (3.12%)	3/130 (2.31%)	5/128 (3.91%)
Gastrointestinal disorders						
Dysphagia † ^A						
# participants affected/at risk	0/151 (0%)	0/40 (0%)	0/41 (0%)	0/64 (0%)	1/130 (0.77%)	0/128 (0%)
# events						
General disorders						
Chest pain † ^A						
# participants affected/at risk	0/151 (0%)	0/40 (0%)	0/41 (0%)	0/64 (0%)	0/130 (0%)	1/128 (0.78%)
# events						
Infections and infestations						
Bronchitis † ^A						
# participants affected/at risk	1/151 (0.66%)	0/40 (0%)	0/41 (0%)	0/64 (0%)	0/130 (0%)	0/128 (0%)

	Placebo	UMEC 62.5 µg QD	UMEC 125 µg QD	VI 25 µg QD	UMEC/VI 62.5/25 µg QD	UMEC/VI 125/25 µg QD
risk						
# events						
Cellulitis † ^A						
# participants affected/at risk	0/151 (0%)	0/40 (0%)	0/41 (0%)	0/64 (0%)	0/130 (0%)	1/128 (0.78%)
# events						
Infective exacerbation of chronic obstructive airways diseas † ^A						
# participants affected/at risk	1/151 (0.66%)	0/40 (0%)	0/41 (0%)	0/64 (0%)	0/130 (0%)	0/128 (0%)
# events						
Subcutaneous abscess † ^A						
# participants affected/at risk	0/151 (0%)	0/40 (0%)	0/41 (0%)	0/64 (0%)	0/130 (0%)	1/128 (0.78%)
# events						
Musculoskeletal and connective tissue disorders						
Musculoskeletal pain † ^A						
# participants affected/at risk	0/151 (0%)	0/40 (0%)	0/41 (0%)	0/64 (0%)	0/130 (0%)	1/128 (0.78%)
# events						

	Placebo	UMEC 62.5 µg QD	UMEC 125 µg QD	VI 25 µg QD	UMEC/VI 62.5/25 µg QD	UMEC/VI 125/25 µg QD
Osteoarthritis † ^A						
# participants affected/at risk	1/151 (0.66%)	0/40 (0%)	0/41 (0%)	0/64 (0%)	0/130 (0%)	0/128 (0%)
# events						
Neoplasms benign, malignant and unspecified (incl cysts and polyps)						
Bladder cancer † ^A						
# participants affected/at risk	0/151 (0%)	0/40 (0%)	0/41 (0%)	1/64 (1.56%)	0/130 (0%)	0/128 (0%)
# events						
Lung adenocarcinoma † ^A						
# participants affected/at risk	0/151 (0%)	0/40 (0%)	0/41 (0%)	0/64 (0%)	1/130 (0.77%)	0/128 (0%)
# events						
Lung neoplasm malignant † A						
# participants affected/at risk	0/151 (0%)	0/40 (0%)	0/41 (0%)	0/64 (0%)	1/130 (0.77%)	0/128 (0%)
# events						
Metastases to central nervous system † ^A						

	Placebo	UMEC 62.5 µg QD	UMEC 125 µg QD	VI 25 µg QD	UMEC/VI 62.5/25 µg QD	UMEC/VI 125/25 µg QD
# participants affected/at risk	0/151 (0%)	0/40 (0%)	0/41 (0%)	0/64 (0%)	1/130 (0.77%)	0/128 (0%)
# events						
Rectal cancer † ^A						
# participants affected/at risk	0/151 (0%)	0/40 (0%)	1/41 (2.44%)	0/64 (0%)	0/130 (0%)	0/128 (0%)
# events						
Nervous system disorders						
Illrd nerve paresis † ^A						
# participants affected/at risk	1/151 (0.66%)	0/40 (0%)	0/41 (0%)	0/64 (0%)	0/130 (0%)	0/128 (0%)
# events						
Respiratory, thoracic and mediastinal disorders						
Chronic obstructive pulmonary disease † ^A						
# participants affected/at risk	1/151 (0.66%)	0/40 (0%)	0/41 (0%)	0/64 (0%)	0/130 (0%)	2/128 (1.56%)
# events						
Pulmonary embolism † ^A						
# participants affected/at	0/151 (0%)	1/40 (2.5%)	0/41 (0%)	0/64 (0%)	0/130 (0%)	0/128 (0%)

	Placebo	UMEC 62.5 µg QD	UMEC 125 µg QD	VI 25 µg QD	UMEC/VI 62.5/25 µg QD	UMEC/VI 125/25 µg QD
risk						
# events						
Skin and subcutaneous tissue disorders						
Leukocytoclastic vasculitis † A						
# participants affected/at risk	0/151 (0%)	0/40 (0%)	0/41 (0%)	1/64 (1.56%)	0/130 (0%)	0/128 (0%)
# events						
Vascular disorders						
Deep vein thrombosis † ^A						
# participants affected/at risk	0/151 (0%)	1/40 (2.5%)	0/41 (0%)	0/64 (0%)	0/130 (0%)	0/128 (0%)
# events						

† Indicates events were collected by systematic assessment.

A Term from vocabulary, MedDRA

Other Adverse Events

Frequency Threshold Above Which Other Adverse Events are Reported: 3%

	Placebo	UMEC 62.5 µg QD	UMEC 125 µg QD	VI 25 µg QD	UMEC/VI 62.5/25 µg QD	UMEC/VI 125/25 µg QD
Total # participants affected/at risk	31/151 (20.53%)	5/40 (12.5%)	14/41 (34.15%)	12/64 (18.75%)	20/130 (15.38%)	18/128 (14.06%)

	Placebo	UMEC 62.5 µg QD	UMEC 125 µg QD	VI 25 µg QD	UMEC/VI 62.5/25 µg QD	UMEC/VI 125/25 µg QD
Gastrointestinal disorders						
Dyspnoea † ^A						
# participants affected/at risk	6/151 (3.97%)	0/40 (0%)	1/41 (2.44%)	1/64 (1.56%)	0/130 (0%)	1/128 (0.78%)
# events						
Toothache † ^A						
# participants affected/at risk	1/151 (0.66%)	0/40 (0%)	2/41 (4.88%)	0/64 (0%)	1/130 (0.77%)	0/128 (0%)
# events						
Infections and infestations						
Nasopharyngitis † ^A						
# participants affected/at risk	10/151 (6.62%)	4/40 (10%)	4/41 (9.76%)	1/64 (1.56%)	8/130 (6.15%)	2/128 (1.56%)
# events						
Sinusitis † ^A						
# participants affected/at risk	3/151 (1.99%)	0/40 (0%)	2/41 (4.88%)	3/64 (4.69%)	2/130 (1.54%)	0/128 (0%)
# events						
Upper respiratory tract infection † ^A						

	Placebo	UMEC 62.5 µg QD	UMEC 125 µg QD	VI 25 µg QD	UMEC/VI 62.5/25 µg QD	UMEC/VI 125/25 µg QD
# participants affected/at risk	1/151 (0.66%)	0/40 (0%)	0/41 (0%)	2/64 (3.12%)	3/130 (2.31%)	3/128 (2.34%)
# events						
Musculoskeletal and connective tissue disorders						
Arthralgia † ^A						
# participants affected/at risk	2/151 (1.32%)	1/40 (2.5%)	1/41 (2.44%)	0/64 (0%)	6/130 (4.62%)	0/128 (0%)
# events						
Back pain † ^A						
# participants affected/at risk	5/151 (3.31%)	0/40 (0%)	1/41 (2.44%)	2/64 (3.12%)	0/130 (0%)	2/128 (1.56%)
# events						
Musculoskeletal pain † ^A						
# participants affected/at risk	0/151 (0%)	0/40 (0%)	1/41 (2.44%)	2/64 (3.12%)	0/130 (0%)	0/128 (0%)
# events						
Respiratory, thoracic and mediastinal disorders						
Cough † ^A						
# participants affected/at risk	3/151 (1.99%)	0/40 (0%)	1/41 (2.44%)	2/64 (3.12%)	2/130 (1.54%)	5/128 (3.91%)

	Placebo	UMEC 62.5 µg QD	UMEC 125 µg QD	VI 25 µg QD	UMEC/VI 62.5/25 µg QD	UMEC/VI 125/25 µg QD
risk						
# events						
Headache † ^A						
# participants affected/at risk	8/151 (5.3%)	1/40 (2.5%)	4/41 (9.76%)	1/64 (1.56%)	3/130 (2.31%)	6/128 (4.69%)
# events						

† Indicates events were collected by systematic assessment.

A Term from vocabulary, MedDRA

More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.

Limitations and Caveats:

Results Point of Contact:

Name/Official Title: GSK Response Center

Organization: GlaxoSmithKline

Phone: 866-435-7343

Email: